Overexpression of HMGB1 has been shown to reduce the sensitivity of BRAF(V600E) mutant thyroid cancer cells to Vemurafenib by increasing cell viability and decreasing apoptosis and caspase-3 activity [73]. Here, CASP3 is linked to thyroid gland carcinoma.